

Avita Medical's ReCell featured at important US Government Symposium on Emergency Preparedness

Australia, 21 May 2015 — Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today that the company participated, by invitation, in a key US Government Symposium focused on Emergency Preparedness. The presentation to influential delegates addressed how the ReCell® medical device could be a versatile and effective treatment for burns and skin wounds in a mass casualty event.

The Symposium on Accessibility and Development of Tissue Products for Emergency Preparedness was held May 11-12 at the National Archives in Washington DC. During the two days, experts from the government, military, academia and industry explored the country's readiness for dealing with large-scale disasters, looking at issues such as optimal treatments, logistics and the regulatory environment. The event was sponsored by the US Department of Health and Human Services, and was organized by the Office of the Assistant Secretary for Health and the Office of the Assistant Secretary for Preparedness and Response (ASPR) Biomedical Advanced Research and development Authority (BARDA), in collaboration with the Department of Defense.

Andrew Quick, Avita Medical's VP of Research and Technology, presented to the group of some 60 participants on how the ReCell® device originated in Australia, where surgeons were presented with numerous burn victims from the 2002 nightclub terrorist bombing in Bali. He explained to the audience how the device can work in combination with skin grafts and other standard treatments, and that it was a simple and versatile way to deliver a unique Regenerative Epithelial Suspension™ (RES™). Mr Quick presented case studies in which RES had reduced hospital time and delivered superior outcomes for scalds and massive burn injuries.

"ReCell slots directly into a gap in the portfolio of medical countermeasure products for conclusive wound care that minimize hospitalization and burden-of-care, which is critically important in the case of a large-scale event," Mr Quick said. "The product's small footprint, long shelf-life and ease of use are desirable key attributes."

Avita Medical CEO Adam Kelliher said the Symposium was a valuable event for various interested parties to exchange ideas.

"We look forward to continuing our work with US government and military agencies, in tandem with our clinical program for FDA approval, which is fully on track," he said.

ABOUT AVITA MEDICAL LIMITED

Avita Medical (<http://www.avitamedical.com/>) develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell®, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. ReCell is not available for sale in the United States; in the United States, ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.

#

FOR FURTHER INFORMATION:

Avita Medical Ltd
Adam Kelliher
Chief Executive Officer
Phone: +44 (0) 1763 269 772
Email: akelliher@avitamedical.com

Avita Medical Ltd
Tim Rooney
Chief Financial Officer
Phone: + 1 (818) 356-9400
Email: trooney@avitamedical.com

Avita Medical Ltd
Gabriel Chiappini
Company Secretary
Phone: +61(0) 8 9474 7738
Email: gabriel@laurus.net.au